Literature DB >> 6280605

Acyclovir - a review of the preclinical and early clinical data of a new antiherpes drug.

D Brigden, P Fiddian, A E Rosling, T Ravenscroft.   

Abstract

A review of the literature on acyclovir (Zovirax), a new antiherpes drug, with particular activity against herpes simplex virus types I and II and also against varicella-zoster, Epstein-Barr, cytomegalo and herpes B viruses, is presented. The article deals with 'in vitro' and 'in vivo' efficacy in animals, animal toxicity, latency and resistance, the mechanism of action and early clinical experience.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6280605     DOI： 10.1016/0166-3542(81)90011-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  13 in total

1.  Reduced in vivo mutagenesis by mutant herpes simplex DNA polymerase involves improved nucleotide selection.

Authors:  J D Hall; P A Furman; M H St Clair; C W Knopf
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  Acyclovir.

Authors:  M C Timbury
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-30

3.  Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

Authors:  Hideo Nakamura; Hideki Kasuya; John T Mullen; Sam S Yoon; Timothy M Pawlik; Soundararajalu Chandrasekhar; James M Donahue; E Antonio Chiocca; Richard Y Chung; Kenneth K Tanabe
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

4.  Aphidicolin resistance in herpes simplex virus type 1 appears to alter substrate specificity in the DNA polymerase.

Authors:  J D Hall; S Woodward
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

5.  Aphidicolin resistance in herpes simplex virus type I reveals features of the DNA polymerase dNTP binding site.

Authors:  J D Hall; Y S Wang; J Pierpont; M S Berlin; S E Rundlett; S Woodward
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

6.  Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan.

Authors:  Nian-Sheng Tzeng; Chi-Hsiang Chung; Fu-Huang Lin; Chien-Ping Chiang; Chin-Bin Yeh; San-Yuan Huang; Ru-Band Lu; Hsin-An Chang; Yu-Chen Kao; Hui-Wen Yeh; Wei-Shan Chiang; Yu-Ching Chou; Chang-Huei Tsao; Yung-Fu Wu; Wu-Chien Chien
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

7.  Relative activities of acyclovir and BW759 against Aujeszky's disease and equine rhinopneumonitis viruses.

Authors:  E A Rollinson; G White
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

Review 8.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

9.  Activity of 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)thymine against herpes simplex virus in cell cultures and rabbit eyes.

Authors:  M D Trousdale; A B Nesburn; T L Su; C Lopez; K A Watanabe; J J Fox
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

10.  Successful treatment of herpes labialis with topical acyclovir.

Authors:  A P Fiddian; J M Yeo; R Stubbings; D Dean
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.